Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEX-TBI: Dexmedetomidine for Agitation in TBI
NCT06620393Phase 3Not yet recruiting
- Start
- Oct 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in psychomotor agitation comparing Dexmedetomidine with Placebo (2 arms). Primary endpoint: Protocol adherence at 2 years. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
dexmedetomidine
03
Conditions
psychomotor agitation
Beyond the preview
Go deeper on NCT06620393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06620393.